A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : MAAs

Search Conditions:
Search Keyword : MAAs
Search Method : Exact match.
Research Area:

Abbreviation: MAAs
Appearance Frequency: 305 time(s)
Long forms: 28

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
mycosporine-like amino acids
(149 times)
(54 times)
UVR (22 times)
PAR (14 times)
UV (14 times)
1993 Evidence Regarding the UV Sunscreen Role of a Mycosporine-Like Compound in the Cyanobacterium Gloeocapsa sp.
Mycosporine-like amino acids
(56 times)
(29 times)
M2G (5 times)
UVR (5 times)
MAA (4 times)
2002 Mycosporine-2-glycine is the major mycosporine-like amino acid in a unicellular cyanobacterium (Euhalothece sp.) isolated from a gypsum crust in a hypersaline saltern pond.
melanoma-associated antigens
(27 times)
(17 times)
CTLs (4 times)
TRP-2 (3 times)
DTH (2 times)
1982 Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies.
myositis-associated autoantibodies
(15 times)
(6 times)
MSAs (14 times)
DM (4 times)
IIM (4 times)
2001 Autoantibody profiles in the sera of European patients with myositis.
Minimum audible angles
(11 times)
(9 times)
HRTF (2 times)
IIDs (1 time)
ILDs (1 time)
1985 Localization of pure tones and click trains by untrained humans.
Mandibular advancement appliances
(9 times)
(5 times)
AHI (4 times)
OSA (4 times)
AI (2 times)
2002 A comparative study of two mandibular advancement appliances for the treatment of obstructive sleep apnoea.
multi-assay algorithms
(7 times)
(3 times)
BED-CEIA (3 times)
HRM (2 times)
CI (1 time)
2013 Cross-sectional HIV incidence estimation in HIV prevention research.
marketing authorization applications
(6 times)
(4 times)
EU (3 times)
EMA (2 times)
CHMP (1 time)
2010 Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
membrane-active agents
(3 times)
(1 time)
AMPs (2 times)
CDs (1 time)
ES (1 time)
2012 Ion pore formation in lipid bilayers and related energetic considerations.
10  melanoma-associated Ags
(2 times)
Allergy and Immunology
(2 times)
gD (1 time)
HMW-MAA (1 time)
scFv (1 time)
1998 Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells.
11  model aromatic amines
(2 times)
Environmental Health
(2 times)
CPT (1 time)
ETS (1 time)
2004 Determination of aniline and related mono-aromatic amines in indoor air in selected Canadian residences by a modified thermal desorption GC/MS method.
12  mycotic aortic aneurysms
(2 times)
General Surgery
(2 times)
EVAR (1 time)
2014 Therapeutic opinion on endovascular repair for mycotic aortic aneurysm.
13  macrophage-associated antibodies
(1 time)
(1 time)
ALL (1 time)
AML (1 time)
FAB (1 time)
1994 Assessment of the value of immunohistochemistry in the subtyping of acute leukemia on routinely processed bone marrow biopsy specimens with particular reference to macrophage-associated antibodies.
14  major artery aneurysms
(1 time)
(1 time)
EVT (1 time)
MMD (1 time)
2020 The prospects and pitfalls in the endovascular treatment of moyamoya disease-associated intracranial aneurysms.
15  Market Access Agreements
(1 time)
Health Services
(1 time)
CAs (1 time)
CEDs (1 time)
PEPs (1 time)
2017 The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
16  market approval authorisation
(1 time)
(1 time)
EPARs (1 time)
FDA (1 time)
ICH (1 time)
2013 Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
17  marketing authorisations
(1 time)
Allergy and Immunology
(1 time)
CAT (1 time)
CHMP (1 time)
EC (1 time)
2015 Regulatory landscape for cell therapy--EU view.
18  membrane active antimicrobials
(1 time)
PMBs (1 time)
2017 Hydrophilic Phage-Mimicking Membrane Active Antimicrobials Reveal Nanostructure-Dependent Activity and Selectivity.
19  mercaptoalkanoic acids
(1 time)
(1 time)
AAAs (1 time)
ABA (1 time)
ADA (1 time)
2016 Aminoalkanoic Acids as Alternatives to Mercaptoalkanoic Acids for the Linker-Assisted Attachment of Quantum Dots to TiO2.
20  Mesh aluminum alloys
(1 time)
Environmental Health
(1 time)
--- 2015 A study on the characteristics of the deflagration of hydrogen-air mixture under the effect of a mesh aluminum alloy.
21  Michael addition acceptors
(1 time)
Complementary Therapies
(1 time)
AP (1 time)
QR (1 time)
2012 Quinone reductase (QR) inducers from Andrographis paniculata and identification of molecular target of andrographolide.
22  Monoclonal antibody assays
(1 time)
Drug Therapy
(1 time)
HPLC (1 time)
SEE (1 time)
1994 A rapid monoclonal antibody blood theophylline assay; lack of cross-reactivity with enprofylline.
23  monocyclic aromatic alkylanilines
(1 time)
(1 time)
2,6-DMA (1 time)
3,5-DMA (1 time)
3,5-DMAP (1 time)
2015 Protective effects of ascorbic acid against the genetic and epigenetic alterations induced by 3,5-dimethylaminophenol in AA8 cells.
24  Monocyclic aromatic amines
(1 time)
(1 time)
QSAR (1 time)
1997 Review of mutagenicity of monocyclic aromatic amines: quantitative structure-activity relationships.
25  motion analysis applications
(1 time)
(1 time)
ACL (1 time)
ACLR (1 time)
2019 Using a Mobile Application to Assess Knee Valgus in Healthy and Post-Anterior Cruciate Ligament Reconstruction Participants.
26  MSCs co-overexpressing Ang-1 and Akt
(1 time)
(1 time)
Ang-1 (1 time)
MSCs (1 time)
2006 Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair.
27  mycosporine amino acid-like substances
(1 time)
(1 time)
--- 2012 Characteristics and role of the exocellular polysaccharides produced by five cyanobacteria isolated from phototrophic biofilms growing on stone monuments.
28  trans-morpholine amino acids
(1 time)
(1 time)
GS (1 time)
2010 Gramicidin S derivatives containing cis- and trans-morpholine amino acids (MAAs) as turn mimetics.